(4/13, Columbus) reports, “Frontline niraparib (Zejula) in addition to bevacizumab (Avastin) as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response (PR) to frontline platinum-based chemotherapy with bevacizumab,” phase 2 data show. Findings were issued for the virtual SGO 2020 Annual Meeting.
